跳至主要内容

Immunoglobulin G, Monitoring of Primary Immunodeficiency Treatment Profile

CPT 82784; 82787(x4)
Synonyms
  • IgG Subclasses
  • IgG1,2,3,4
  • Intravenous Immunoglobulin Treatment Monitoring
  • Primary Immunodeficiency Treatment Monitoring

Test Details

Methodology

Immunologic

Result Turnaround Time

3 - 5 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Test Includes

Quantitation of IgG1, IgG2, IgG3, IgG4, total IgG

Use

Monitoring the treatment of patients with intravenous IgG infusions who exhibit primary immunodeficiency with recurrent infections

Special Instructions

State patient's age on the test request form.

Limitations

This procedure is not suitable for the measurement of samples containing rheumatoid factor, paraproteins, other circulating immune complexes (CICs), or for lipemic or hemolyzed samples due to the unpredictable degree of non-specific light scatter these sample types may generate. The results obtained from measuring IgG subclasses should not be used in assessing atopy in allergic patients.

Footnotes

1. Orange JS, Hossny EM, Weiler CR, et al. Use of Intravenous Immunoglobulin in Human Disease: A Review of Evidence of Members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma, and Immunology. J Allergy Clin Immunol 2006 Apr; 117:S525-553.16580469
2. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of Trough IgG on Pneumonia Incidence in Primary Immunodeficiency: A Meta-analysis of Clinical Studies. Clin Immunol 2010 Oct; 137(1):21-30.20675197
3. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG Level in Primary Immunodeficiency Disease: The IgG Level That Protects Against Recurrent Infection. J Allergy Clin Immunol 2008 Jul; 122(1):210-212.18602574
4. Vidarsson G, Dekkers G, Rispens T. IgG Subclasses and Allotypes: from structure to effector functions. Front Immunol. 2014 Oct; 5:520.25368619

Custom Additional Information

In the past decades, administration of exogenous pooled human immunoglobulin for intravenous use (IVIG) has become an important therapy in clinical practice. Maintaining higher trough levels (>800 mg/dL of total IgG) in order to protect patients from recurrent infections have been reported.1-3 Percentages of relative abundance of human IgG subclasses for total IgG are reported to be approximately 60% for IgG1, 32% for IgG2, 4% for IgG3, and 4% for IgG4.4

Specimen Requirements

Specimen

Serum

Volume

3 mL

Minimum Volume

1.8 mL

Container

Red-top tube or gel-barrier tube

Collection Instructions

Transfer serum to a plastic transport tube.

Stability Requirements

Temperature

Period

Room temperature

3 days

Refrigerated

7 days

Frozen

13 days

Freeze/thaw cycles

Stable x3

Reference Range

Total IgG trough level: >800 mg/dL

Note: Maintaining trough levels of total IgG above 800 mg/dL is reported to prevent serious bacterial illness, enteroviral meningoencephalitis, and pneumonia, but target trough levels may vary with individual patient.1-3

Approximate targets for trough levels for IgG subclasses (mg/dL)4:

IgG1

IgG2

IgG3

IgG4

>480

>256

>32

>32

Storage Instructions

Refrigerate

Causes for Rejection

Gross lipemia; hemolysis

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
123225 IgG, Treatment Monitoring 123226 Immunoglobulin G, Qn, Serum mg/dL 2465-3
123225 IgG, Treatment Monitoring 123227 IgG, Subclass 1 mg/dL 2466-1
123225 IgG, Treatment Monitoring 123228 IgG, Subclass 2 mg/dL 2467-9
123225 IgG, Treatment Monitoring 123229 IgG, Subclass 3 mg/dL 2468-7
123225 IgG, Treatment Monitoring 123230 IgG, Subclass 4 mg/dL 2469-5
Order Code123225
Order Code NameIgG, Treatment Monitoring
Order Loinc
Result Code123226
Result Code NameImmunoglobulin G, Qn, Serum
UofMmg/dL
Result LOINC2465-3
Order Code123225
Order Code NameIgG, Treatment Monitoring
Order Loinc
Result Code123227
Result Code NameIgG, Subclass 1
UofMmg/dL
Result LOINC2466-1
Order Code123225
Order Code NameIgG, Treatment Monitoring
Order Loinc
Result Code123228
Result Code NameIgG, Subclass 2
UofMmg/dL
Result LOINC2467-9
Order Code123225
Order Code NameIgG, Treatment Monitoring
Order Loinc
Result Code123229
Result Code NameIgG, Subclass 3
UofMmg/dL
Result LOINC2468-7
Order Code123225
Order Code NameIgG, Treatment Monitoring
Order Loinc
Result Code123230
Result Code NameIgG, Subclass 4
UofMmg/dL
Result LOINC2469-5